Pattern Recognition Receptor-reactivity Screening of Liver Transplant Patients: Potential for Personalized and Precise Organ Matching to Reduce Risks of Ischemia-reperfusion Injury.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 28 11 2018
medline: 24 6 2020
entrez: 28 11 2018
Statut: ppublish

Résumé

Pattern recognition receptors (PRRs) on immune and parenchymal cells can detect danger-associated molecular patterns (DAMPs) released from cells damaged during ischemia-reperfusion injury (IRI), in heart attack or stroke settings, but also as an unavoidable consequence of solid organ transplantation. Despite IRI being a significant clinical problem across all solid organ transplants, there are limited therapeutics and patient-specific diagnostics currently available. We screened portal blood samples obtained from 67 human liver transplant recipients both pre- [portal vein (PV) sample] and post-(liver flush; LF) reperfusion for their ability to activate a panel of PRRs, and analyzed this reactivity in relation to biopsy-proven IRI. PV samples from IRI+ orthotopic liver transplantation (OLT) patients (n = 35) decreased activation of hTLR4- and hTLR9-transfected cells, whereas PV from IRI- patients (n = 32) primarily increased hTLR7 and hNOD2 activation. LF samples from OLT-IRI patients significantly increased activation of hTLR4 and hTLR9 over IRI- LF. In addition, the change from baseline reactivity to hTLR4/9/NOD2 was significantly higher in IRI+ than IRI- OLT patients. These results demonstrate that TLR4/7/9 and NOD2 are involved in either promoting or attenuating hepatic IRI, and suggest a diagnostic screening of portal blood for reactivity to these PRRs might prove useful for prediction and/or therapeutic intervention in OLT patients before transplantation.

Sections du résumé

OBJECTIVE AND BACKGROUND
Pattern recognition receptors (PRRs) on immune and parenchymal cells can detect danger-associated molecular patterns (DAMPs) released from cells damaged during ischemia-reperfusion injury (IRI), in heart attack or stroke settings, but also as an unavoidable consequence of solid organ transplantation. Despite IRI being a significant clinical problem across all solid organ transplants, there are limited therapeutics and patient-specific diagnostics currently available.
METHODS
We screened portal blood samples obtained from 67 human liver transplant recipients both pre- [portal vein (PV) sample] and post-(liver flush; LF) reperfusion for their ability to activate a panel of PRRs, and analyzed this reactivity in relation to biopsy-proven IRI.
RESULTS
PV samples from IRI+ orthotopic liver transplantation (OLT) patients (n = 35) decreased activation of hTLR4- and hTLR9-transfected cells, whereas PV from IRI- patients (n = 32) primarily increased hTLR7 and hNOD2 activation. LF samples from OLT-IRI patients significantly increased activation of hTLR4 and hTLR9 over IRI- LF. In addition, the change from baseline reactivity to hTLR4/9/NOD2 was significantly higher in IRI+ than IRI- OLT patients.
CONCLUSIONS
These results demonstrate that TLR4/7/9 and NOD2 are involved in either promoting or attenuating hepatic IRI, and suggest a diagnostic screening of portal blood for reactivity to these PRRs might prove useful for prediction and/or therapeutic intervention in OLT patients before transplantation.

Identifiants

pubmed: 30480558
doi: 10.1097/SLA.0000000000003085
pmc: PMC6620163
mid: NIHMS1031491
pii: 00000658-202005000-00021
doi:

Substances chimiques

Biomarkers 0
NOD2 protein, human 0
Nod2 Signaling Adaptor Protein 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

922-931

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI128913
Pays : United States
Organisme : NIMHD NIH HHS
ID : L60 MD011903
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI135201
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI120944
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009120
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124319
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI042819
Pays : United States

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
PLoS One. 2014 Nov 04;9(11):e110642
pubmed: 25369327
JCI Insight. 2016 Dec 8;1(20):e89679
pubmed: 27942590
Am J Transplant. 2016 Jun;16(6):1779-87
pubmed: 26752191
J Clin Gastroenterol. 2017 Sep;51(8):677-682
pubmed: 28742731
J Exp Med. 2002 Dec 16;196(12):1645-51
pubmed: 12486107
Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13
pubmed: 2700931
Immunity. 2011 May 27;34(5):680-92
pubmed: 21616437
Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):257-76
pubmed: 21996492
N Engl J Med. 2000 Aug 3;343(5):338-44
pubmed: 10922424
J Intern Med. 2014 Nov;276(5):444-53
pubmed: 25041239
Am J Transplant. 2011 Aug;11(8):1563-9
pubmed: 21668640
Cell. 2013 Aug 29;154(5):962-970
pubmed: 23993090
J Immunol. 2007 Jul 1;179(1):41-4
pubmed: 17579019
Transplantation. 2005 Mar 15;79(5):505-14
pubmed: 15753838
Annu Rev Immunol. 1994;12:991-1045
pubmed: 8011301
Transplant Direct. 2016 Aug 05;2(9):e97
pubmed: 27795989
Liver Transpl. 2007 Oct;13(10):1435-43
pubmed: 17902130
Curr Opin Organ Transplant. 2010 Apr;15(2):167-72
pubmed: 20186059
Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):328-38
pubmed: 10660480
Curr Opin Immunol. 1997 Feb;9(1):4-9
pubmed: 9039775
Am J Transplant. 2013 Jun;13(6):1450-60
pubmed: 23617781
Am J Transplant. 2016 Sep;16(9):2545-55
pubmed: 26946212
Science. 2002 Apr 12;296(5566):301-5
pubmed: 11951032
Ann Surg. 2013 Jan;257(1):27-36
pubmed: 22836216
J Hepatol. 2014 Aug;61(2):418-31
pubmed: 24768755
Curr Opin Immunol. 2001 Feb;13(1):114-9
pubmed: 11154927
Transplantation. 2008 Jun 15;85(11):1625-31
pubmed: 18551070
Am J Transplant. 2013 May;13(5):1327-35
pubmed: 23463950
Immunobiology. 2013 Nov;218(11):1312-21
pubmed: 23962476
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Clin Liver Dis (Hoboken). 2017 Oct 31;10(4):97-99
pubmed: 31186895
Immunol Rev. 2011 Sep;243(1):9-25
pubmed: 21884164
Immunol Rev. 2011 Sep;243(1):99-108
pubmed: 21884170
J Leukoc Biol. 2013 Jun;93(6):847-63
pubmed: 23475577
Expert Rev Gastroenterol Hepatol. 2016 Jun;10(6):665-7
pubmed: 27077275
Cell. 2010 Mar 19;140(6):771-6
pubmed: 20303867

Auteurs

Rebecca A Sosa (RA)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Maura Rossetti (M)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Bita V Naini (BV)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Victoria M Groysberg (VM)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Fady M Kaldas (FM)

Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Ronald W Busuttil (RW)

Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Yu-Ling Chang (YL)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

David W Gjertson (DW)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Jerzy W Kupiec-Weglinski (JW)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Elaine F Reed (EF)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH